Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 140 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 30 Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide
- Record updated
- 9 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Spontaneous ICH
- Age ≥18 years
- Premorbid modified Rankin Scale of ≤3
- TRICH score ≥3
- Within 1 week of ICH
Who cannot take part
- Severe renal impairment, estimated glomerular filtration rate using CKD-EPI formula <30 ml/min/1.73m2
- Hypersensitivity to study drug
- Any conditions that investigator deems that patient is not suitable of any component of the triple pill or antihypertensive medications in general
- Glasgow coma score <9
- Expected life expectancy of six months
- Admission SBP <160mmHg
- Inability to perform home BP monitoring
- Inability to participate in follow-up activity
- Known contraindication to amlodipine
- Known contraindication to valsartan
- Known contraindication to hydrochlorothiazide
This trial is currently available in Hong Kong.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Intracerebral hemorrhage (ICH) is the second most common form of stroke, with an incidence of around 3000 cases per year in Hong Kong. Although it only accounts for around 20-30% of all strokes, ICH is the most severe form of stroke, contributing to 50% of all stroke mortality and the greatest disability burden in stroke. For those who survive their ICH, they are at high risk of ICH recurrence, stroke, cardiovascular event and death. Hence, reducing these risks after ICH is a top priority to lessen the disease's healthcare and social burden.
Read full original descriptionShow less
Hypertension is the main driver for ICH, and achieving blood pressure (BP) control significantly reduces the risk of recurrent ICH, stroke and cardiovascular events. However, only 50% of ICH survivors achieved BP control after ICH. This is because ICH patients represent a unique hypertensive population with more difficult-to-control BPs, with many requiring ≥3 antihypertensive medications. Many reasons contribute to uncontrolled hypertension, but inadequate prescription of medication is the most actionable cause. The notion of an upfront prescription of a triple antihypertensive regimen (triple pill) soon after ICH could consequent better BP control, but there are concerns of excessive lowering of BP, particularly in older patients, which has been associated with increased mortality. This approach may also not be suitable for ICH patients with cerebral amyloid angiopathy where the elevated admission BP may be due to acute hypertensive response rather than underlying hypertension. Additionally, the general use of upfront triple pill in all ICH would have healthcare implications, as triple pills are more expensive compared to conventional antihypertensive medications.
To facilitate individualized treatment, a predictive score, the TRICH score, was recently developed and validated to identify patients who require triple pills after ICH. Therefore, the current TRIACT study aims to test the clinical application and benefit of the TRICH score for the upfront prescription of triple antihypertensive medication after ICH to enable prompt achievement of BP control.
The 2 groups in the trial
- Triple antihypertensive medication groupExisting treatment, for comparison
Triple antihypertensive medication Amlodipine 5mg/ Valsartan 160mg/ Hydrochlorothiazide 12.5mg, either as triple pill or three individual component drugs, on Day 3 after ICH. Dosage will be increased to Amlodipine 10/ Valsartan 160/ Hydrochlorothiazide 25, if SBP remained \>130 mmHg on Day 7, or early if deemed necessary. Further anti-hypertensive medication titration will be made by the research team in consultation with the treating medical team as appropriate during the study period.
Treatment: Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide
- Control groupNo study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- TRIple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure ConTrol With the TRICH Score
- Record updated
- 9 March 2026